BioCentury
ARTICLE | Company News

Arcturus, Alcobra merging

October 6, 2017 5:55 PM UTC

RNA medicines company Arcturus Therapeutics Inc. (San Diego, Calif.) will merge with Alcobra Ltd. (NASDAQ:ADHD) in a stock deal expected to close this quarter. Alcobra shareholders will own about 40% of the combined company; Arcturus shareholders will own the remainder.

The merged company will utilize Arcturus' unlocked nucleomonomer agent (UNA) oligomer chemistry and its lipid-enabled and unlocked nucleic acid modified RNA delivery (LUNAR) nanoparticle delivery platform. Earlier this year, the company partnered with the Cystic Fibrosis Foundation to fund development of a preclinical CF candidate (see BioCentury, June 1)...